HSPC-sparing treatments for RB-positive abnormal cellular proliferation
View Patent ↗This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
1. A method for the treatment of cancer in a host, wherein the cancer is Retinoblastoma-positive (Rb) and selected from the group consisting of breast cancer, colon cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, and glioblastoma, comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the compound is
or its pharmaceutically acceptable salt.
3. The method of claim 1 , wherein the compound is
or its pharmaceutically acceptable salt.
4. The method of claim 1 , wherein the cancer is breast cancer.
5. The method of claim 1 , wherein the cancer is colon cancer.
6. The method of claim 1 , wherein the cancer is ovarian cancer.
7. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
8. The method of claim 1 , wherein the cancer is glioblastoma.
9. The method of claim 1 , wherein the host is a human.
10. The method of claim 1 , wherein the compound is administered in combination with another chemotherapeutic agent.
11. The method of claim 10 , wherein the chemotherapeutic agent does not rely on cellular proliferation for its anti-cancer activity.
12. The method of claim 1 , wherein the compound is administered orally.
13. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
14. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
15. The method of claim 1 , wherein the cancer is prostate cancer.
16. A method for the treatment of Retinoblastoma-positive breast cancer in a host comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is
or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 , wherein the host is a human.
18. The method of claim 16 , wherein the compound is administered orally.
19. The method of claim 16 , wherein the compound is administered in combination with a chemotherapeutic agent.
20. The method of claim 19 , wherein the chemotherapeutic agent is an mTOR inhibitor.
21. The method of claim 19 , wherein the chemotherapeutic agent is a PI3 kinase inhibitor.
22. The method of claim 19 , wherein the chemotherapeutic agent is a dual mTOR-PI3K inhibitor.
23. The method of claim 19 , wherein the chemotherapeutic agent is a MEK inhibitor.
24. The method of claim 19 , wherein the chemotherapeutic agent is a RAS inhibitor.
25. The method of claim 19 , wherein the chemotherapeutic agent is an ALK inhibitor.
26. The method of claim 19 , wherein the chemotherapeutic agent is a HSP inhibitor.
27. The method of claim 19 , wherein the chemotherapeutic agent is letrozole.
28. The method of claim 19 , wherein the chemotherapeutic agent is capecitabine.
29. The method of claim 19 , wherein the chemotherapeutic agent is tamoxifen.
30. The method of claim 19 , wherein the chemotherapeutic agent is pictilisib.
31. The method of claim 19 , wherein the chemotherapeutic agent is buparlisib.
32. The method of claim 19 , wherein the chemotherapeutic agent is everolimus.
33. The method of claim 19 , wherein the chemotherapeutic agent is goserelin.
34. The method of claim 19 , wherein the chemotherapeutic agent is anastrozole.
35. The method of claim 19 , wherein the chemotherapeutic agent is doxorubicin.
36. The method of claim 19 , wherein the chemotherapeutic agent is paclitaxel.
37. The method of claim 19 , wherein the chemotherapeutic agent is a monoclonal antibody which targets the human epidermal growth factor receptor 2 (HER-2).
38. The method of claim 37 , wherein the monoclonal antibody is trastuzumab.
39. The method of claim 37 , wherein the monoclonal antibody is conjugated with a chemotherapeutic agent.
40. The method of claim 39 , wherein the conjugated monoclonal antibody is ado-trastuzumab emtansine.
41. The method of claim 16 , wherein the breast cancer is estrogen-receptor positive.
42. A method for the treatment of Retinoblastoma (Rb)-positive prostate cancer in a host comprising administering an effective amount of a compound to a host in need thereof, wherein the compound is
or a pharmaceutically acceptable salt thereof.
43. The method of claim 42 , wherein the host is a human.
44. The method of claim 42 , wherein the compound is administered orally.
45. The method of claim 42 , wherein the compound is administered in combination with a chemotherapeutic agent.
46. The method of claim 45 , wherein the chemotherapeutic agent is prednisone.
47. The method of claim 45 , wherein the chemotherapeutic agent is docetaxel.
48. The method of claim 45 , wherein the chemotherapeutic agent is mitoxantrone.
49. The method of claim 45 , wherein the chemotherapeutic agent is bicalutamide.
50. The method of claim 45 , wherein the chemotherapeutic agent is flutamide.
51. The method of claim 45 , wherein the chemotherapeutic agent is nilutamide.
52. The method of claim 10 , wherein the chemotherapeutic agent is an mTOR inhibitor.
53. The method of claim 10 , wherein the chemotherapeutic agent is a PI3K inhibitor.
54. The method of claim 10 , wherein the chemotherapeutic agent is a dual mTOR-PI3K inhibitor.
55. The method of claim 10 , wherein the chemotherapeutic agent is a MEK inhibitor.
56. The method of claim 10 , wherein the chemotherapeutic agent is a RAS inhibitor.
57. The method of claim 10 , wherein the chemotherapeutic agent is an ALK inhibitor.
58. The method of claim 10 , wherein the chemotherapeutic agent is a HSP inhibitor.
59. The method of claim 10 , wherein the chemotherapeutic agent is letrozole.
60. The method of claim 10 , wherein the chemotherapeutic agent is capecitabine.
61. The method of claim 10 , wherein the chemotherapeutic agent is tamoxifen.
62. The method of claim 10 , wherein the chemotherapeutic agent is pictilisib.
63. The method of claim 10 , wherein the chemotherapeutic agent is buparlisib.
64. The method of claim 10 , wherein the chemotherapeutic agent is everolimus.
65. The method of claim 10 , wherein the chemotherapeutic agent is goserelin.
66. The method of claim 10 , wherein the chemotherapeutic agent is anastrozole.
67. The method of claim 10 , wherein the chemotherapeutic agent is doxorubicin.
68. The method of claim 10 , wherein the chemotherapeutic agent is paclitaxel.
69. The method of claim 10 , wherein the chemotherapeutic agent is prednisone.
70. The method of claim 10 , wherein the chemotherapeutic agent is docetaxel.
71. The method of claim 10 , wherein the chemotherapeutic agent is mitoxantrone.
72. The method of claim 10 , wherein the chemotherapeutic agent is bicalutamide.
73. The method of claim 10 , wherein the chemotherapeutic agent is flutamide.
74. The method of claim 10 , wherein the chemotherapeutic agent is nilutamide.